logo
Full-fat milk vs low-fat milk: Study finally reveals which is healthier for your heart

Full-fat milk vs low-fat milk: Study finally reveals which is healthier for your heart

Independent17 hours ago
A decades-long study has finally revealed how healthy full-fat and low-fat milk are, with researchers concluding that one is safer for your heart.
Experts analysed three decades of health data and found the fat level of milk influenced a person's risk of dying of heart disease.
The study published in the The American Journal of Clinical Nutrition used data from three cardiovascular health screenings conducted between 1974 and 1988.
Researchers in Norway tracked the data of 73,860 individuals, with an average age of 41, over 33 years and recorded 26,393 deaths, including 8,590 from cardiovascular disease.
They found those who drank full-fat milk had a higher mortality risk in than those who drank low-fat milk.
Researchers were able to make this comparison due to a unique historical context. In the 1970s, most people in Norway drank whole milk, but by the 1980s more people drank low-fat milk. This meant researchers were able to investigate the long-term health consequences of drinking both of these milk types.
Those who drank the most milk in the study had a 22 per cent increased risk of all-cause mortality and a 12 per cent increased risk of death from cardiovascular disease in comparison to those who drank the least.
But further analysis revealed whole milk in particular was driving this increased risk of death.
When researchers compared full-fat and low-fat milk and adjusted for how much they drank, they found consuming low-fat milk was associated with a 11 per cent lower mortality risk and a 7 per cent lower risk of cardiovascular disease than consuming whole milk.
The findings remained consistent even after excluding early deaths or participants with pre-existing conditions.
However, low-fat milk drinkers tended to be females, have higher education and not smoke, in comparison to whole fat milk drinkers who frequently reported being current smokers.
Study authors concluded: 'Associations between milk intake and cardiovascular disease and all-cause mortality varied by type of milk, with positive associations found for whole milk and a modestly inverse association with ischemic heart disease and all-cause mortality was found for low-fat milk when compared with whole milk.'
The results are in line with current NHS health advice. Most of the fat in milk and dairy foods is saturated fat which when eating in large amounts can contribute to weight gain, the NHS explains. A diet high in saturated fat can also lead to raised levels of cholesterol in the blood, increasing the risk of having a heart attack or a stroke.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CureVac settles mRNA patent dispute litigation with Pfizer and BioNTech
CureVac settles mRNA patent dispute litigation with Pfizer and BioNTech

Reuters

time2 hours ago

  • Reuters

CureVac settles mRNA patent dispute litigation with Pfizer and BioNTech

Aug 7 (Reuters) - German drugmaker CureVac ( opens new tab and GSK (GSK.L), opens new tab reached an agreement with BioNTech ( opens new tab and Pfizer (PFE.N), opens new tab on Thursday to resolve a years-long patent dispute related to mRNA-based COVID-19 vaccines, CureVac said. As part of the settlement, CureVac and GSK will receive a combined payment of $740 million and single-digit royalties on sales of COVID-19 vaccines in the U.S. going forward. CureVac will also grant BioNTech and Pfizer a non-exclusive license to manufacture, use, import and sell mRNA-based COVID-19 and influenza products in the U.S. The settlement comes after BioNTech agreed to acquire its domestic peer CureVac in a $1.25 billion all-stock deal in June. Three years ago, CureVac had filed a patent lawsuit against BioNTech over its use of mRNA technology, seeking fair compensation from the company and two of its subsidiaries for infringement of its intellectual property rights. CureVac had said that its claim to intellectual property rights was based on more than two decades of work on mRNA technology, some of which was used by BioNTech and Pfizer for the development and sale of their Comirnaty coronavirus vaccine. CureVac's efforts to develop an mRNA-based COVID-19 vaccine did not come to fruition during the pandemic, whereas BioNTech and its partner Pfizer chalked up more than $40 billion in combined vaccine sales in 2021 and 2022.

Butterfly from Southern Europe spotted in UK for first time
Butterfly from Southern Europe spotted in UK for first time

BBC News

time2 hours ago

  • BBC News

Butterfly from Southern Europe spotted in UK for first time

A species of butterfly previously only found in Southern Europe has been seen in the UK for the first time, according to charity Butterfly have tracked the Southern Small White butterfly's rapid expansion northwards through Europe over recent first UK sighting was confirmed at Landguard Bird Observatory in Suffolk, after a volunteer managed to snap a is not yet clear what has driven the species' expansion, though a warming climate is thought to be part of the answer. Until recently, the range of the Southern Small White was limited to Southern Europe, in particular south-east Conservation says the species was first spotted north of the Alps in France and Germany in 2008, and since then it has gradually extended its range, reaching the Netherlands in 2015 and Calais in first UK visitor was a female butterfly and was spotted at Landguard Nature Reserve on 2 August by volunteer Will Brame, according to BirdGuides. Its identification as a Southern Small White was confirmed by butterfly expert Chris van Swaay of Dutch Butterfly Corton, a County Recorder for Butterflies in Suffolk, contacted us about the story through Your Voice, Your BBC it is thought a warming climate has played a role in its spread, modelling from a 2008 Climatic Risk Atlas of European Butterflies showed that even under the most extreme warming scenarios the species was not expected in the Low Countries until after 2050. Dr Dan Hoare, Director of Nature Recovery at Butterfly Conservation, said the species had made an "ecological leap"."There are species that are rare in the UK and periodically over the years they have turned up in ones and twos... but it's not really indicating any significant shift in our fauna," he said."Southern Small White is very different. It's basically colonised northern Europe from the Swiss Alps to the North Sea in the last decade, moving north at a rate of about 100 kilometres [62 miles] a year."But whether the species stays long term is yet to be seen, he says, as its food source is a garden species called Candytuft that is not as widely planted species has never been a migrant to the UK, and is yet to have been recorded breeding here, which is what a resident species would do.

CureVac settles patent dispute litigation with Pfizer and BioNTech
CureVac settles patent dispute litigation with Pfizer and BioNTech

Reuters

time2 hours ago

  • Reuters

CureVac settles patent dispute litigation with Pfizer and BioNTech

Aug 7 (Reuters) - CureVac ( opens new tab said on Thursday that the company and GSK (GSK.L), opens new tab have entered an agreement to a resolve patent dispute with Pfizer (PFE.N), opens new tab and BioNTech ( opens new tab related to mRNA-based COVID-19 vaccines. As part of the settlement, CureVac and GSK will receive a combined payment of $740 million and single-digit royalties on sales of COVID-19 vaccines in the U.S. going forward. CureVac will also grant BioNTech and Pfizer a non-exclusive license to manufacture, use, import and sell mRNA-based COVID-19 and influenza products in the U.S.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store